1Serruys PW, Degertekin M, Tanabe K, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound "analysis from the TAXUS 11 trial. Circulation,2004,109 : 627-633.
2Grube E, Silber S, HaupUnann KE, el al. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation, 2003,107 : 38-42.
3Tanabe K, Serruys PW, Grube E, et al. ln-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation, 2003,107:559-564.
4Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces instent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation, 2003,107:517-520.
5Gershlick A, De Scheeardex I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial.Circulation, 2004,109:487-493.
9[2]Dordunoo SK,Jackson JK,Arsenault LA,et al.Taxol encapsulation in poly caproactone microsphere.Cancer Che Mother Pharmacol,1995,36:276.
10[4]Joner M,Finn AV,Farb A,et al.Pathdogy of drug-eluting stents in humans:delayed healing and late thrombotic risk.J Am Coll Cardial,2006,48:193-202.
